Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

…, M Perez-Toledo, GD Banham, N Wall, CL Clarke… - The Lancet, 2021 - thelancet.com
We sought to compare neutralising antibody responses between seronaive haemodialysis
patients and the healthy individuals we have already reported on as part of the Legacy study. …

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

M Prendecki, T Thomson, CL Clarke, P Martin… - The Lancet, 2021 - thelancet.com
Data are shown as median with IQR. Statistical analysis is by MannWhitney test (A) or
KruskallWallis test with Dunns posthoc correction (B).(A) Kidney transplant recipients who …

[HTML][HTML] Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection

CL Clarke, M Prendecki, A Dhutia, J Gan, C Edwards… - Kidney international, 2021 - Elsevier
… Author links open overlay panel Candice L. Clarke 1 2 5 , Maria Prendecki 1 2 5 , Amrita
Dhutia 2 , Jaslyn Gan 2 , Claire Edwards 2 , Virginia Prout 2 , Liz Lightstone 1 2 , Eleanor Parker …

[HTML][HTML] Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients

…, B Sandhu, C Seneschall, J Gan, CL Clarke… - …, 2022 - thelancet.com
Background Solid organ transplant recipients have attenuated immune responses to SARS-CoV-2
vaccines. In this study, we report on immune responses to 3rd- (V3) and 4th- (V4) …

Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death

J Gisby, CL Clarke, N Medjeral-Thomas, TH Malik… - Elife, 2021 - elifesciences.org
End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19. We
measured 436 circulating proteins in serial blood samples from hospitalised and non-hospitalised …

[HTML][HTML] Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence

JS Gisby, NB Buang, A Papadaki, CL Clarke… - Nature …, 2022 - nature.com
Patients with end-stage kidney disease (ESKD) are at high risk of severe COVID-19. Here,
we perform longitudinal blood sampling of ESKD haemodialysis patients with COVID-19, …

[HTML][HTML] Comparison of vaccine effectiveness against the omicron (B. 1.1. 529) variant in hemodialysis patients

…, S Gleeson, P Martin, T Thomson, CL Clarke… - Kidney international …, 2022 - Elsevier
Results A total of 1121 in-center hemodialysis patients were included in the analysis; all
patients underwent weekly screening for SARS-CoV-2 infection via reverse transcriptase-…

[HTML][HTML] Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease …

P Martin, S Gleeson, CL Clarke, T Thomson… - The Lancet Regional …, 2022 - thelancet.com
Background People with end-stage kidney disease, including people on haemodialysis, are
susceptible to greater COVID-19 related morbidity and mortality. This study compares the …

Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines

M Prendecki, T Thomson, CL Clarke, P Martin… - MedRxiv, 2021 - medrxiv.org
Background Attenuated immune responses to mRNA SARS-CoV-2 vaccines have been
reported in solid organ transplant recipients. Most studies have assessed serological responses …

Comparison of immunogenicity between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in a large haemodialysis population

CL Clarke, P Martin, S Gleeson, T Thomson… - Medrxiv, 2021 - medrxiv.org
Background Limited data exists on the immunogenicity of vector-based SARS-CoV-2
vaccines in patients with kidney disease. Given their use in over 180 countries, such data is of …